08 August 2018
Visiongain’ has launched a new Pharmaceutical Report Hepatitis C Therapies Market 2017-2027: Revenue Forecasts for Hepatitis C Therapeutics, Direct-Acting Antivirals, Ribavirin, Protease Inhibitors, Polymerase Inhibitors, Interferons & R&D.
The report forecasts the overall hepatitis C therapies market will multiply in revenues from 2017 to 2027. The pharmaceutical segment is evolving. Newly approved medications are achieving commercial success with some products gaining blockbuster status. Visiongain reports the strength of the HCV drugs market is its oral antiviral treatments enabling shorter treatment regimens and higher cure rates, reportedly with fewer side effects than the standard care – peginterferon and ribavirin. Steady growth is predicted for the hepatitis C market during the forecast period of this report. This is primarily due to the strong pipeline for antiviral treatments and increased awareness of Hepatitis C. Several drugs are expected to be approved during the forecast period.
The visiongain report analyst commented “The future of the hepatitis C market looks promising, as a number of new therapies are coming on to the market. Recent and expected forthcoming approvals of all-oral regimens, particularly interferon-free and also ribavirin-free, will stimulate growth of the market and feed the demand for more efficacious and convenient treatments. Although these regimens will come at a greater cost than the current standard of care – peginterferon and ribavirin – they have fewer side effects and are a welcome advance by patients and physicians alike.
In 2016, the greatest interest in the hepatitis C market was the development of protease and polymerase antivirals. Several companies have molecules in phase II and III trials, with at least 5 expected to gain approval within the first half of the forecast period. Although the overall world hepatitis C drugs market earned $19bn in 2016, we expect it to reach $20.7bn in 2021. The hepatitis C market is rapidly evolving and will contribute billions to the pharmaceutical market in the coming 10 years.”
The new report shows revenue forecasts to 2025 at overall world market, submarket, product and national level. It forecasts these world-level submarkets:
• Interferon treatments
• Oral antiviral therapy.
That investigation predicts revenues of eight leading products in the market, including Harvoni, Sovaldi, Epclusa, Daklinza,Zepatier, Sunverpa Pegasys,, PegIntron and Olysiol. Revenue forecasts are also included of Research, data and analyses covering activities of Gilead Sciences, Johnson & Johnson, Roche, Bristol-Myers Squibb, Merck & Co., AbbVie, Achillion Pharmaceuticals and other companies.
Analyses cover R&D and commercial news, show two research interviews and predict revenues to 2027 in leading regional markets. This includes the US, Japan, Germany, the UK, France, Italy, Spain (EU5 group), Brazil, Russia, India and China (BRIC countries).
Hepatitis C Therapies: World Industry, R&D and Market Forecasts 2017-2027 adds to visiongain’s range of reports on industries and markets in healthcare. Together these studies cover medical devices, diagnostics and pharmaceuticals.
Leading companies featured in the report who are developing Hepatitis C therapeutics include Gilead Sciences, Merck and Co., Bristol Myers Squibb, Roche, Janssen, Medivir, Abbvie, Achillion Pharmaceuticals.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.
19 April 2021
The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.
12 April 2021
Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.
09 April 2021
The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.